179 related articles for article (PubMed ID: 18351583)
1. The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides.
Hodoniczky J; Sims CG; Best WM; Bentel JM; Wilce JA
Biopolymers; 2008; 90(5):595-603. PubMed ID: 18351583
[TBL] [Abstract][Full Text] [Related]
2. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
3. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Colquhoun AJ; Venier NA; Vandersluis AD; Besla R; Sugar LM; Kiss A; Fleshner NE; Pollak M; Klotz LH; Venkateswaran V
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):346-52. PubMed ID: 22614062
[TBL] [Abstract][Full Text] [Related]
4. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity.
Kawata H; Ishikura N; Watanabe M; Nishimoto A; Tsunenari T; Aoki Y
Prostate; 2010 May; 70(7):745-54. PubMed ID: 20058237
[TBL] [Abstract][Full Text] [Related]
5. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
6. Box-Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: stability assessment.
Kudarha R; Dhas NL; Pandey A; Belgamwar VS; Ige PP
Pharm Dev Technol; 2015; 20(5):608-18. PubMed ID: 24785784
[TBL] [Abstract][Full Text] [Related]
7. Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for Peptide aptamer delivery into the nucleus.
Yoshikawa T; Sugita T; Mukai Y; Yamanada N; Nagano K; Nabeshi H; Yoshioka Y; Nakagawa S; Abe Y; Kamada H; Tsunoda S; Tsutsumi Y
J Mol Biol; 2008 Jul; 380(5):777-82. PubMed ID: 18571668
[TBL] [Abstract][Full Text] [Related]
8. Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex.
Patil AL; Pore YV; Kuchekar BS; Late SG
Pharmazie; 2008 Apr; 63(4):282-5. PubMed ID: 18468387
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
10. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
11. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
12. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Van Poppel H
Eur Urol; 2007 Jul; 52(1):115. PubMed ID: 17270341
[No Abstract] [Full Text] [Related]
14. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Bassetto M; Ferla S; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
Eur J Med Chem; 2016 Aug; 118():230-43. PubMed ID: 27131065
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
Gravina GL; Festuccia C; Millimaggi D; Tombolini V; Dolo V; Vicentini C; Bologna M
Urology; 2009 Aug; 74(2):452-7. PubMed ID: 19285710
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.
Kim D; Jeon C; Kim JH; Kim MS; Yoon CH; Choi IS; Kim SH; Bae YS
Exp Cell Res; 2006 May; 312(8):1277-88. PubMed ID: 16466653
[TBL] [Abstract][Full Text] [Related]
17. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic studies on the synthesis of bicalutamide.
Asaad N; Fillery S
Org Biomol Chem; 2009 Feb; 7(4):678-86. PubMed ID: 19194583
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
Parent EE; Dence CS; Jenks C; Sharp TL; Welch MJ; Katzenellenbogen JA
J Med Chem; 2007 Mar; 50(5):1028-40. PubMed ID: 17328524
[TBL] [Abstract][Full Text] [Related]
20. Membrane permeable peptide vectors: chemistry and functional design for the therapeutic applications.
Futaki S
Adv Drug Deliv Rev; 2008 Mar; 60(4-5):447. PubMed ID: 18077052
[No Abstract] [Full Text] [Related]
[Next] [New Search]
